Excelsior Biopharma Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-183.17	-98.71	-91.01	-33.76	-15.65
Depreciation & Amortization	71.68	70.96	46.22	26.06	28.65
Loss (Gain) From Sale of Assets	0.65	-	-	-	-
Loss (Gain) From Sale of Investments	-	-	-	-	0.21
Loss (Gain) on Equity Investments	-2.18	-0.25	-	-	-
Stock-Based Compensation	0.28	0.33	0.26	0.04	-
Provision & Write-off of Bad Debts	-2.56	2.25	0.98	-3.67	4.47
Other Operating Activities	-1.8	2.81	6.75	0.78	5.53
Change in Accounts Receivable	-45.81	-30.53	-27.17	82.26	-35.87
Change in Inventory	17.75	-85.65	-28.7	16.02	71.88
Change in Accounts Payable	-38.78	42.43	-16.92	-49.79	-18.52
Change in Other Net Operating Assets	45.22	-3.44	-25.15	-32.46	15.13
Operating Cash Flow	-138.72	-99.8	-134.75	5.49	55.82
Operating Cash Flow Growth	-	-	-	-90.17%	-89.28%
Capital Expenditures	-36.95	-257.15	-35.66	-7.78	-2.88
Sale of Property, Plant & Equipment	2.25	-	-	-	-
Investment in Securities	11.45	-55.5	199.74	-200	-6.01
Other Investing Activities	-1.15	5.62	-17.47	8.54	-1.8
Investing Cash Flow	-24.4	-307.03	146.62	-199.24	-10.68
Short-Term Debt Issued	159.61	0.01	0.01	-	-
Long-Term Debt Issued	-	110	-	-	-
Total Debt Issued	159.61	110.01	0.01	-	-
Short-Term Debt Repaid	-	-0.01	-0.01	-	-
Long-Term Debt Repaid	-51.97	-53.98	-317.23	-13.73	-12.64
Total Debt Repaid	-51.97	-53.99	-317.24	-13.73	-12.64
Net Debt Issued (Repaid)	107.64	56.02	-317.23	-13.73	-12.64
Repurchase of Common Stock	-	-	-	-	-23.74
Common Dividends Paid	-	-	-	-	-46.67
Other Financing Activities	0.74	0.98	-	-	-
Financing Cash Flow	108.38	56.99	-317.23	-13.73	-83.04
Net Cash Flow	-54.74	-349.84	-305.36	-207.49	-37.9
Free Cash Flow	-175.67	-356.95	-170.41	-2.3	52.95
Free Cash Flow Growth	-	-	-	-	-89.60%
Free Cash Flow Margin	-19.56%	-41.41%	-22.09%	-0.34%	3.96%
Free Cash Flow Per Share	-3.81	-7.74	-3.71	-0.05	1.14
Cash Interest Paid	7.65	7.96	1.36	0.88	1.12
Cash Income Tax Paid	12.4	8.36	8.38	8.28	3.46
Levered Free Cash Flow	-104.35	-311.04	-139.51	4.43	59.32
Unlevered Free Cash Flow	-99.49	-306.02	-135.53	7.15	62.16
Change in Working Capital	-21.62	-77.19	-97.95	16.03	32.61

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.